Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2016-05-25

Clinical Trial Update: Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Liposarcoma [Phase 2]

View source ↗

Summary

Phase 2 study of pazopanib in patients with surgically unresectable or metastatic liposarcoma completed; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Pazopanib (Votrient) (Pazopanib)

Snippet

Sponsor: Vector Oncology | Conditions: Liposarcoma, Surgically Unresectable Liposarcoma | Phase 2 | Status: COMPLETED | Results posted: 2016-05-25